rodent models is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
== Toxicity == Following inhalation, chloromethane is rapidly absorbed into the bloodstream and distributed throughout the body's tissues. It is primarily metabolized through conjugation with glutathione by the GST enzyme. This process depletes cellular glutathione levels and transforms the chloromethane into toxic intermediates, including formaldehyde and formate. These products are eventually integrated into the "one-carbon pool" for biosynthesis or exhaled as carbon dioxide. A secondary, less dominant metabolic pathway involves oxidation by cytochrome P450. Methyl chloride is considered to act as a significant central nervous system (CNS) depressant. Acute inhalation produces effects similar to alcohol intoxication, including respiratory depression, dizziness, blurred vision, lack of coordination, and slurred speech; severe cases can progress to convulsions, coma, and death. Occupational safety standards have established a threshold limit value (TLV) and a maximum allowable concentration (MAC) of 50 ppm as a time-weighted average to mitigate these risks. Prolonged or repeated exposure has been linked to potential mutagenic effects and chronic organ toxicity in animal models. However, the EPA classifies its carcinogenic potential in humans as "cannot be determined" due to species-specific metabolic differences (specifically the activity of the CYP2E1 enzyme in mouse kidneys but not in humans).
The American Society for Biochemistry and Molecular Biology (ASBMB) is a learned society that was founded on December 26, 1906, at a meeting organized by John Jacob Abel (Johns Hopkins University). The roots of the society were in the American Physiological Society, which had been formed some 20 years earlier. ASBMB is the US member of the International Union of Biochemistry and Molecular Biology. The ASBMB was originally called the American Society of Biological Chemists, before obtaining its current name in 1987. The society is based in Rockville, Maryland. ASBMB's mission is to advance the science of biochemistry and molecular biology through publication of scientific and educational journals, the organization of scientific meetings, advocacy for funding of basic research and education, support of science education at all levels, and by promoting the diversity of individuals entering the scientific workforce. The organization currently has over 12,000 members.
The magnetic mass separators are able to separate isobars by mass number, however they are unable to sort isotopes of the same mass. If an experiment requires a higher degree of chemical purity, it will need the beam to have an additional separation, by proton number. RILIS provides this separation by using step-wise resonance photo-ionisation, involving precisely tuned laser wavelengths matched exactly to a specific element's successive electron transition energies. Ionisation will only occur of the desired element, and the other elements within the ion-source will remain unchanged. This process of laser ionisation takes place in a hot metal cavity to provide the spatial confinement needed for the atomic vapour to be illuminated. A high frequency laser system is needed to ionise the atom before it leaves the cavity. All in all, the ISOLDE facility provides 1300 isotopes from 75 elements in the periodic table.
5β-Pregnane, also known as 17β-ethyletiocholane or as 10β,13β-dimethyl-17β-ethyl-5β-gonane, is a steroid and a parent compound of a variety of steroid derivatives. It is one of the epimers of pregnane, the other being 5α-pregnane. Derivatives of 5β-pregnane include the naturally occurring steroids 5β-dihydroprogesterone, pregnanolone, epipregnanolone, pregnanediol, and pregnanetriol, and the synthetic steroids hydroxydione, renanolone, ORG-20599, and SAGE-217. These derivatives include metabolites of progesterone and endogenous and synthetic neurosteroids. Etiocholane Gonane
Sources: en.wikipedia.org
Heart failure - Giving 2.5 times of previous oral dose twice daily for those with acute decompensated heart failure is a reasonable strategy. However, daily assessment of clinical response is needed to adjust the subsequent doses. Edema - Volume overload associated with liver cirrhosis, heart failure, or nephrotic syndrome Cerebral edema - intravenous furosemide can be combined with mannitol to initiate rapid diuresis. However, the optimum duration of such treatment remains unknown. Frequent fluid status monitoring is required to prevent intravascular volume depletion which leads to reduced cerebral perfusion. A bolus intravenous dose of 10 or 20 mg of furosemide can be administered and then followed by intravenous bolus of 2 or 3% hypertonic saline to increase the serum sodium level. Pulmonary edema - Slow intravenous bolus dose of 40 to 80 mg furosemide at 4 mg per minute is indicated for patients with fluid overload and pulmonary edema. Such dose can be repeated after 20 minutes. After the bolus, a continuous intravenous infusion can be given at 5 to 10 mg per hour. For those with underlying renal impairment or severe heart failure, up to 160 to 200 mg bolus dose can be given. Hypertension - A systematic review by the Cochrane Hypertension group assessing the anti-hypertensive effects of loop diuretics found only a modest reduction in blood pressure when compared to placebo. According to Joint National Committee (JNC-8) guidelines, the first line treatment of hypertension is thiazide diuretics. The use of loop diuretics is not mentioned in this guideline.
As of 2026, seven condemned people had survived medical problems when the executioners could not access a vein, and an eighth, Christa Pike, had survived receiving the drugs, according to Robin M. Maher, executive director of the Death Penalty Information Center.
First Minister of Wales Eluned Morgan offers Plaid Cymru an open invitation to support the Welsh Government's budget, scheduled to be delivered by Finance Secretary Mark Drakeford on 10 December. Wales's health secretary, Jeremy Miles announces that private healthcare will be used to help reduce the patient backlog in the NHS, with £50m allocated for health to be given to Wales's health boards to provide more appointments, tests and treatments. 20 November – Peter Kyle, the Secretary of State for Science, Innovation and Technology, tells the BBC that a ban on social media for under-16s in the UK is "on the cards". 21 November – Stephen Flynn, the SNP's leader at Westminster, says he will not seek a dual mandate by standing for the Scottish Parliament while he remains an MP. 22 November – Downing Street indicates that Israeli prime minister Benjamin Netanyahu would face arrest if he travelled to the UK following the issuing of an international arrest warrant for war crimes by the International Criminal Court. Former prime minister Gordon Brown publicly declares his opposition to a new law on assisted dying. 23 November – The UK government advertises for a new negotiator which it hopes will deliver a "reset" of the UK's relationship with the European Union. Secretary of State for Justice Shabana Mahmood writes to her constituents saying she is "profoundly concerned" about the Terminally Ill Adults (End of Life) Bill, not only for religious reasons but because of what it would mean for the state if one of its roles became helping people to die.
Sources: en.wikipedia.org
== Description == Boea hygroscopica is an herbaceous or woody plant growing no taller than 1 m (3 ft 3 in). The flowers are 20–22 millimetres (0.8–0.9 in) in diameter and the peduncles (flower stems) are 85–90 millimetres (3.3–3.5 in) long. There are 5 petals and they are dimorphic, with 2 larger ones about 10 by 8 mm (0.4 by 0.3 in) and 3 smaller ones about 10 by 5 mm (0.4 by 0.2 in).
== BOLD-100 derivatives == BOLD-100 is sodium trans-[tetrachlorobis (1H-indazole) ruthenate(III)] with cesium as an intermediate salt form. BOLD-100 was developed from KP1339 (also known as IT-139 or NKP-1339) which is also sodium trans-[tetrachlorobis (1H-indazole) ruthenate(III)], but has different manufacturing methods and purity profiles. The names are often used interchangeably. The precursor to BOLD-100 is KP1019, which is the indazole salt equivalent. KP1019 previously entered Phase 1 clinical trials but development was halted due to low solubility in water, leading to the development of KP1339 and BOLD-100 which are readily soluble in water. KP1019 and KP1339 were invented by Dr. Keppler at the University of Vienna.
Much of the universe's water is produced as a byproduct of star formation. The formation of stars is accompanied by a strong outward wind of gas and dust. When this outflow of material eventually impacts the surrounding gas, the shock waves that are created compress and heat the gas. The water observed is quickly produced in this warm dense gas. On 22 July 2011, a report described the discovery of a gigantic cloud of water vapor containing "140 trillion times more water than all of Earth's oceans combined" around a quasar located 12 billion light years from Earth. According to the researchers, the "discovery shows that water has been prevalent in the universe for nearly its entire existence". Water has been detected in interstellar clouds within the Milky Way. Water probably exists in abundance in other galaxies, too, because its components, hydrogen, and oxygen, are among the most abundant elements in the universe. Based on models of the formation and evolution of the Solar System and that of other star systems, most other planetary systems are likely to have similar ingredients.
== Causes == The cause of IBM is unknown. IBM likely results from the interaction of a number of genetic and environmental factors. There are two major theories about how sIBM is caused. One hypothesis suggests that the inflammation-immune reaction, caused by an unknown trigger – likely an undiscovered virus or an autoimmune disorder – is the primary cause of sIBM and that the degeneration of muscle fibers and protein abnormalities are secondary features. Despite the arguments "in favor of an adaptive immune response in sIBM, a purely autoimmune hypothesis for sIBM is untenable because of the disease's resistance to most immunotherapy." The second school of thought advocates the theory that sIBM is a degenerative disorder related to aging of the muscle fibers and that abnormal, potentially pathogenic protein accumulations in myofibrils play a key causative role in sIBM (apparently before the immune system comes into play). This hypothesis emphasizes the abnormal intracellular accumulation of many proteins, protein aggregation and misfolding, proteosome inhibition, and endoplasmic reticulum (ER) stress. One review discusses the "limitations in the beta-amyloid-mediated theory of IBM myofiber injury." Dalakas (2006) suggested that a chain of events causes IBM – some sort of virus, likely a retrovirus, triggers the cloning of T cells. These T cells appear to be driven by specific antigens to invade muscle fibers.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.